Mavrilimumab

Mavrilimumab
Mavrilimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target GMCSF receptor &alpha-chain
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 1085337-57-0 N
ATC code None
UNII 1158JD1P9A YesY
Chemical data
Formula C6706H10438N1762O2104S54 
Mol. mass 143.2 kDa
 N(what is this?)  (verify)

Mavrilimumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1]

Mavrilimumab was developed by MedImmune, Inc.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf. 
v · d · eMonoclonal antibodies for the immune system
Immune system ("-l(i[m])-")
Human ("-limu-")

immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab

immune activation: Ipilimumab • Tremelimumab

other: Bertilimumab • Zanolimumab
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
immunosuppressive: Aselizumab • Apolizumab • Benralizumab† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412§
non-immunosuppressive: Ibalizumab†
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • Ustekinumab
Humanized ("-kizu-", "-kinzu-")
Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • Olokizumab
Inflammatory lesions ("-les-")
Mouse ("-leso-")
Besilesomab • Fanolesomab‡ • Lemalesomab • Sulesomab
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.